Viral-Targeted Nanostructured Drug (VTND) Platform

The outbreak of COVID-19 and subsequent mutant variants has caused millions of deaths and severe acute respiratory illness worldwide. Therapeutics such as monoclonal antibodies, small molecule drugs inhibiting viral replication and immune modulators suppressing hyperinflammation have shown promise, but each comes with limitations including viral variant escape, side effects from high doses of I.V. injection, and lack of localized specificity. The variant outbreaks have emphasized the unmet need for better treatment regimens, particularly those that can simultaneously recognize and bind strongly to different variants, have high targeting specificity to reduce adverse effects and that appropriately target the innate immune system driven lung-infiltration.